drugset / Trial / NCT00703391

A Two Week Study to Assess the Tolerability of AZD9668 in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT00703391

Phase 2 Completed 18 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindBasic science

Summary

The purpose of this study is to assess the tolerability (effect of drug on body) and pharmacokinetics (effect of body on drug) of AZD9668 in patients with mild to moderate COPD

Timeline

Start
2008-06
Primary completion
2008-09
Completion
2008-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Alvelestat Small molecule 30 mg Oral